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To my loving family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less.” 
NL: “Niets in het leven is om bang voor te zijn, het moet alleen begrepen worden. Nu is de 
tijd om meer te begrijpen, zodat we minder bang kunnen zijn.” 
Marie Curie (1867-1934) 
  
 
  
ABSTRACT 
Autoimmunity is a condition in which the ability to tolerate self breaks down, 
resulting in immune responses against the body’s own healthy cells and tissues. Autoimmune 
diseases are complex and multifactorial, and both genetic and environmental factors are 
known to play a crucial role. Using animal models, it is possible to study different aspects of 
arthritis disease development in an environmentally and genetically controlled setting. In this 
thesis, I have investigated the effect of genetic risk loci and the single environmental factor 
sodium chloride (NaCl) on immune cell function and the development of autoimmune 
diseases using mouse models.  
In Paper I, using four congenic sub-loci within the arthritis susceptible Cia9 locus on 
chromosome 1, we found that the NOD.Q polymorphic Fc gamma receptor gene (FcγR) 
cluster located within sub-loci Cia9i and Cia9k, regulated arthritis. Polymorphic FcγR2b and 
FcγR4 were contained in both Cia9i and Cia9k, whereas Cia9i mice also carried polymorphic 
FcγR3. FcγR2b gene and protein expression were downregulated in Cia9i and Cia9k mice, 
whereas FcγR3 was upregulated in Cia9i mice and found downregulated in Cia9k mice 
compared to littermate control mice. This difference in FcγR3 expression affected killing by 
NK cells and phagocytosis by macrophages in vitro and PC61 antibody induced regulatory T 
cell depletion in vivo. Interestingly, arthritis development was regulated by interaction 
between FcγR2b and FcγR3 without affecting anti-collagen type II antibody secretion. These 
results show that polymorphisms in both FcγR2b and FcγR3 regulate the severity of 
inflammatory responses.  
In paper II, we investigated the importance of the system A family of amino acid transporters 
(SNAT), based on an identified congenic locus, as mediators of immune cell function and 
arthritis development. We demonstrated that SNAT proteins affect the initial stages of 
lymphocyte activation by regulating glutamine uptake in the presence of Na+, and that the 
effector phase of arthritis could be suppressed by blocking SNAT proteins.  
Paper III describes the effect of salt (e.g. NaCl) on the development of autoimmunity. Here 
we show that a moderate salt intake affects both T cell and macrophage phenotypes in vitro 
and ex vivo. However, these moderate levels of salt intake did not alter the development of T 
cell-dependent autoimmunity, whereas the dextran sulphate sodium (DSS)-induced colitis 
was exacerbated in mice pre-exposed to salt.  
Taken together, I have shown that the interplay between two genes enhances arthritis disease 
development, whereas a single environmental factor has no impact on arthritis despite 
triggering the immune system. These results contribute to the understanding of the 
mechanism behind complex multifactorial diseases as a small building block towards 
therapeutic intervention. 
  
  
SUMMARY FOR MY FAMILY 
Dutch: Samenvatting 
Ons immuunsysteem beschermt ons dagelijks tegen verschillende ziektekiemen die 
aanwezig zijn in en rondom ons lichaam. Als we toch ziek worden, werkt ons 
immuunsysteem hard om van die infectie af te komen. Dit gaat vaak gepaard met koorts en, 
op celniveau, met infiltrerende immuuncellen die de infectie aanvallen en doden. Om een 
voorbeeld te geven: als een infectie ons lichaam binnenkomt, vallen cellen (zoals 
macrofagen) deze infectie aan om ze te doden. Soms hebben deze macrofagen hulp nodig van 
B-cellen, welke antilichaampjes aanmaken, en T-cellen om van de infectie af te komen. In het 
geval van een auto-immuunziekte worden lichaamseigen cellen aangevallen door het eigen 
immuunsysteem. Het is niet precies bekend waarom dit gebeurd. Wel weten we dat auto-
immuunziektes complex zijn en dat ze kunnen ontstaan door een combinatie van meerdere 
factoren. Een persoon met een “verkeerde” genetische aanleg die bovendien blootgesteld 
wordt aan “verkeerde” omgevingsfactoren heeft een verhoogde kans om een auto-
immuunziekte te ontwikkelen.  
Een welbekend voorbeeld van een auto-immuunziekte is reumatoïde artritis, in de volksmond 
vaak reuma genoemd. Reuma is een ziekte waarin het kraakbeen in gewrichten langzaam 
afgebroken wordt en botvergroeiingen kunnen ontstaan. Symptomen zijn vaak zichtbaar in de 
vingers/handen van patiënten, deze kunnen rood, gezwollen en erg pijnlijk zijn. 
Tegenwoordig kunnen botvergroeiingen vaak voorkomen worden door op tijd in te grijpen 
met het nemen van medicatie en het soepel houden van gewrichten door middel van sporten 
en fysiotherapie. Helaas kunnen reuma en andere auto-immuunziekten tot op heden nog niet 
worden voorkomen. Daarvoor is meer onderzoek nodig.  
Om controle op de genetische aanleg en omgevingsfactoren te hebben, worden muismodellen 
voor verschillende auto-immuunziekten gebruikt. Muizen worden ziek nadat ze geïnjecteerd 
zijn met lichaamseigen eiwitten of moleculen voor de desbetreffende ziekte. In deze scriptie 
heb ik voornamelijk gewerkt met muismodellen voor reuma. Met behulp van muismodellen, 
heb ik onderzoek gedaan naar het effect van genetische risico factoren en naar het effect van 
keukenzout (NaCl) op de functie van immuun cellen en de ontwikkeling van auto-
immuunziekten.  
In artikel I, heb ik gebruik gemaakt van speciaal gefokte muizen die een genetische aanleg 
hebben voor reuma. Reuma ontwikkeld nadat de muizen geïnjecteerd zijn met collageen type 
II (CII), aanwezig in het kraakbeen, of met antilichaampjes tegen CII. Met behulp van deze 
muizen heb ik gekeken naar de functie van specifieke receptoren die antilichaampjes kunnen 
binden (Fc gamma receptoren, FcγR) en aanwezig zijn op immuuncellen zoals macrofagen en 
B cellen. Een defect in het DNA en eiwit van twee van deze receptoren (FcγR2b en FcγR3) 
leidde tot meer agressieve reuma. Uit mijn onderzoek blijkt ook dat dit afhankelijk is van de 
functie van macrofagen.  
In artikel II, heb ik onderzocht wat de functie is van bepaalde aminozuur transporters, 
genaamd SNAT, op de ontwikkeling van reuma. SNAT eiwitten reguleren een gedeelte van 
immuuncelactivatie (voornamelijk T-cellen) door het opnemen van glutamine in de 
aanwezigheid van een zout ion (Na+). Het blokkeren van deze eiwitten onderdrukt reuma in 
muizen. 
In artikel III, heb ik gekeken naar het effect van keukenzout op de ontwikkeling van drie 
verschillende auto-immuunziekten (reuma, multipele sclerose (MS) en inflammatoire 
darmziekten). Op celniveau zien we dat immuuncellen zoals T-cellen en macrofagen meer 
autoreactief worden, wat inhoudt dat ze ziekten kunnen veroorzaken. Muizen krijgen een 
zoutwater oplossing (1% NaCl) of normaal kraanwater te drinken alvorens ze worden 
blootgesteld aan het stofje dat ze ziek maakt. Gedurende de ziekte worden de symptomen van 
de muizen in de twee verschillende groepen (zoutwater en normaal kraanwater) bijgehouden. 
We zien dat het innemen van keukenzout in deze concentratie geen effect heeft op de 
ontwikkeling van reuma of MS, maar dat het de symptomen voor de inflammatoire 
darmziekten verergerd.  
Samengevat heb ik in artikel I aangetoond dat de nauwe samenwerking van twee Fc gamma 
receptoren de ontwikkeling van reuma verergerd. Dit bevestigt de complexiteit van de ziekte. 
Bovendien is mijn onderzoek in artikel III in overeenstemming met onderzoek in reuma 
patiënten, waarin geen directe link tussen overtallige zout inname en reuma was aangetoond. 
Desalniettemin, heb ik bevestigd dat overtallige inname van zout een negatief effect heeft op 
celniveau en op de ontwikkeling van inflammatoire darmziekten.  
Al met al heb ik met mijn onderzoek bijgedragen, al is het een klein puzzelstukje, aan het 
beter begrijpen van de ontwikkeling van complexe auto-immuunziekten zoals reuma.  
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1 INTRODUCTION 
 “Autoimmunity is a condition in which the ability to tolerate self breaks down and 
the body ends up under attack as the immune system mistakes the body’s cells for enemies 
(1).”  
Here I intend to give a brief overview of the immune system and what is known about the 
development of autoimmunity. I will further discuss the important role of genetics and 
environmental factors in the pathogenesis of different autoimmune diseases, with the main 
focus on rheumatoid arthritis and mouse models thereof. Furthermore, I will explain why the 
use of animal models is so important to study genetics and environmental factors. The genes 
and their functions studied in this thesis are the genes for the sodium-coupled neutral amino 
acid transporters and the Fc gamma receptors. “A salty story” reflects on the impact of 
increased salt exposure on immune cell function and autoimmunity as described in paper III. 
The overall aim of this thesis is to contribute to the understanding of mechanisms behind 
complex multifactorial diseases as a small building block on the road to therapeutic 
intervention.  
1.1 THE IMMUNE SYSTEM 
From birth and onwards we live in symbiosis with different microorganisms, such as 
bacteria, fungi, viruses and parasites, without constantly developing diseases. It is the 
immune system that protects us. The immune system is our body’s defence mechanism and 
consists of numerous cell types (immune cells), tissues and molecules that help us fight 
infections and to remove dead and damaged cells from the body. A classical division is made 
between the innate and adaptive immune system. Once pathogens have crossed the physical 
barriers of the body, such as skin, the gastrointestinal and the respiratory mucosa, the innate 
immune system gets activated. This mechanism of first line defence is nonspecific and fast, 
acting within minutes or hours after exposure to an infectious pathogen, either by acute 
inflammation or through antiviral defence. When activated, innate cells differentiate into 
short-lived effector cells to clear the pathogen. If needed, innate immune responses stimulate 
adaptive immunity through antigen-presentation. The adaptive immune system consists of 
humoral immunity and cell-mediated immunity, and is characterized by specificity, diversity, 
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specialization and memory. It therefore requires several days to get activated. The innate 
immune system is evolutionary older than the more specialized adaptive immune system and 
is found not only in vertebrates, but also in invertebrates and plants. Studies in insects have 
demonstrated the absence of adaptive immunity and therewith that of autoimmune diseases 
(2). Although immunological memory is considered to be exclusive for the adaptive immune 
system, there is an increasing body of evidence that suggests that innate immune responses 
exhibit memory characteristics after the first encounter with a pathogen. As reviewed by 
Netea et al., this memory of trained immunity is defined as an increased response to a 
secondary infection that can be exerted towards the same microorganism or cross-protection 
observed as phenotypic changes in NK cells and macrophages (3).  
In the following section, the various cell types and characteristics of the innate and adaptive 
immune system, as well as the connection between both, will be reviewed.  
1.1.1 The innate immune system 
Cells of the innate immune system are both from myeloid and lymphoid lineages. 
Myeloid cells include granulocytes (neutrophils, basophils and eosinophils), monocytes, 
macrophages, dendritic cells and mast cells and are involved in acute inflammation. These 
cells cannot distinguish between individual pathogens, since they lack specific receptors, but 
they express pattern recognition receptors (PRR) with which they can recognize pathogen-
associated molecular patterns (PAMP) present on pathogens, and can thus distinguish self 
from non-self. Damaged or necrotic cells are also cleared by innate immune cells through 
their recognition of damage-associated molecular patterns (DAMP) on those cells. One of the 
most described innate immune cell receptors are toll-like receptors (TLR) (4). An example is 
TLR-4, which is specific for bacterial lipopolysaccharide (LPS) and this receptor is often 
activated in in vitro macrophage assays (5). Activated TLRs either enhance expression of 
cytokines (which are soluble proteins that mediate immune and inflammatory reactions) and 
other proteins to promote phagocytosis or the production of type 1 interferons (IFN) to 
mediate antiviral defence. One of the cells involved in the latter, are natural killer (NK) cells. 
NK cells are, among innate lymphoid cells (ILCs), NK T cells and γδ T cells, cells of the 
lymphoid compartment of the innate immune system (4). For the scope of this thesis, 
neutrophils, macrophages and NK cells will be described further. Neutrophils and 
macrophages are thought to be important regulators in arthritis development (6), studied in 
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papers I, II and III. Moreover, macrophage activation has been assessed in papers I, II and III, 
whereas the cytotoxic function of NK cells has been studied in paper I. 
Neutrophils are circulating leukocytes that are recruited to the site of infection or tissue 
damage and are highly abundant in blood. They are short lived cells and are the first cell type 
to respond to bacterial and fungal infection. After they are recruited to the site of infection or 
tissue damage, they ingest microbes through a process called phagocytosis. Once microbes 
are phagocytosed, they will fuse with lysosomes and will be killed by enzymes and toxic 
substances such as reactive oxygen species (ROS) and nitric oxide (NO), often referred to as 
oxidative burst. Inflammatory cytokines and immune complexes can enhance this 
phagocytosis process, after which neutrophils kill themselves either through apoptosis or by 
forming neutrophil extracellular traps (NETs). The latter is a process called NETosis and is 
considered to be pro-inflammatory, whereas apoptosis renders anti-inflammatory effects, 
attracting macrophages to remove the apoptotic cell (7–9).  
Macrophages are monocyte-derived cells that reside in different organs and tissues 
throughout the body. The clearance of apoptotic cells is induced by cytokines such as 
interleukin (IL)-4 and IL-13. These apoptotic macrophages are important for tissue repair and 
can produce anti-inflammatory cytokines such as IL-10. Macrophages activated by microbial 
TLR-ligands and IFN-y are involved in phagocytosis and the production of ROS. Activated 
macrophages are also important effector cells within the adaptive immune system. A relevant 
example is their recognition of antibody-coated (opsonized) microbes through their Fc 
gamma receptors (receptors that recognize the Fc portion of immunoglobulin G (IgG), 
described in detail below), which induces antibody-dependent cellular phagocytosis (ADCP). 
Another component that can help clear pathogens, either in the absence or presence of 
circulating antibodies, are complement proteins, which are circulating as well as membrane-
associated proteins. When activated, they opsonize microbes and stimulate phagocytosis, 
promote leukocyte (e.g. neutrophils and macrophages) recruitment to the site of inflammation 
(C3a and C5a) and lyse the microbe (10).  
As briefly mentioned, innate immune cells secrete cytokines upon activation. One of the 
cytokines secreted by macrophages during phagocytosis is IL-12. IL-12 can activate NK cells 
to produce IFN-y that in turn activates macrophages to kill the phagocytosed microbes. A 
direct function of NK cells is to kill host cells infected by microbes. NK cells contain 
cytoplasmic granules filled with perforin and granzymes. Upon activation, NK cells release 
these granules that then enter the infected cells and activate enzymes, inducing apoptosis. NK 
cells distinguish infected cells from non-infected cells through the expression levels of class I 
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major histocompatibility complex (MHC-I) molecules. A healthy cell expresses MHC-I, 
which is recognized by an inhibitory receptor on NK cells, preventing NK cells to attack. A 
virus-infected or stressed cell has reduced expression of MHC-I, together with high 
expression of ligands for activating NK cell receptors, which results in NK cell activation and 
killing of the infected cell (11). One such activating receptor is CD16, or Fc gamma receptor 
3, which binds to antibody-coated cells and results in killing by antibody-dependent cellular 
cytotoxicity (ADCC).  
A further link between the innate and adaptive immune system is the process of antigen 
presentation by antigen presenting cells (APCs) such as dendritic cells (DCs). DCs are 
present in the epithelia and subepithelial tissues and use various membrane receptors to bind 
microbes. After endocytosis of the microbe antigens, the engulfed proteins get processed into 
peptides for loading onto MHC molecules (12). This process leads to release of inflammatory 
cytokines such as TNF and IL-1. Subsequently, DCs upregulate co-stimulatory molecules 
such as CD40, CD80 and CD86 and the chemokine receptor CCR7. This induces migration 
to lymph nodes where they mature into APCs. By presenting the peptide antigens on their 
MHC molecules to T cells, T cells will get activated. 
1.1.2 The adaptive immune system 
As mentioned above, the adaptive immune system is antigen specific and gets 
triggered several days into the progression of an infection.  
Both T cells and B cells originate from bone marrow hematopoietic stem cells, but whereas B 
cells develop and mature in the bone marrow, T cells migrate to the thymus to develop. Here 
these thymocytes undergo a series of maturation steps, expressing different surface markers. 
During early development, thymocytes don’t express the T cell co-receptors CD4 and CD8 
and are called double negative (DN: CD4-CD8-) T cells. These DN cells are further 
subdivided by CD44 and CD25 into four stages (DN1-4). At DN3 (CD44-CD25+) β-
selection and rearrangement of the T cell receptor (TCR) occurs. This leads to expression of 
both CD4 and CD8 (double positive) after which the α-chain of the TCR is rearranged. This 
is followed by positive and negative selection. Only thymocytes that don’t interact too strong 
or too weak with MHC class I or MHC class II are positively selected and eventually become 
CD8+ or CD4+ cells, whereas other cells are killed by apoptosis. These positive selected cells 
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then undergo negative selection, where thymocytes that interact too strongly with self-antigen 
will be killed by apoptosis or selected to become Regulatory T cells (Tregs) (4, 13).  
After maturation, naïve CD4+ and CD8+ T cells migrate to peripheral lymphoid organs, where 
they can get activated after their TCR recognizes peptide antigens presented by APCs on their 
MHC-II or MHC-I molecules, respectively. This leads to T cell expansion and differentiation 
into effector cells. These effector cells enter the circulation and migrate, together with other 
leukocytes, to the site of infection where they encounter the antigen. CD4 T cells activate 
(help) leukocytes to induce phagocytosis and CD8 T cells kill infected cells either directly or 
through release of cytokines that activate macrophages to kill. However, T cells need a 
second and third signal to become activated, otherwise they will become anergic instead. A 
second signal is provided by the APCs through co-stimulatory molecules (CD28 on T cells 
and CD80/CD86 molecules on APCs), and cytokines are signal three. 
CD4 T cells are also called T helper cells (Th). Upon activation these cells differentiate into 
specific subsets, including Th1, Th2, Th17 and Tregs. They differ in their cytokine 
production profile, surface marker receptors and effector functions. Th1 cells secrete IFNγ, 
IL-2, IL-10 and TNF and promote macrophage activation and cytotoxic T cell proliferation to 
induce phagocytosis and killing of mibrobes. Upon antigen recognition, Th1 cells express 
CD40L on their surface that binds to the CD40 receptor on macrophages and professional 
APCs. Differentiation of Th1 cells is induced by cytokines such as IL-27, IL-12 and IFNγ. 
Th2 cells expand in the presence of IL-4 and IL-2 or IL-7. They mount immune responses 
against large extracellular pathogens such as parasites and are required for humoral 
immunity. Th2 cells secret IL-4, IL-5, IL-9, IL-13 and IL-25. Th17 cells secrete IL-17 and 
IL-22 that stimulate chemokine secretion and recruitment of neutrophils and macrophages as 
mentioned above. In mice, Th17 cells develop in the presence of IL-6 and TGF-β, whereas 
IL-1β, IL-6, IL-21 and IL-23 are needed in humans (4, 14).  
After an immune response has been carried out and the pathogen has been cleared, T and B 
cell responses should be terminated to avoid inflammatory tissue damage. Activated T cells 
start expressing inhibitory receptors such as cytotoxic T lymphocyte antigen (CTLA)-4 that 
outcompetes CD28 for binding to costimulatory CD80/86 molecules on APCs. It also 
dampens downstream TCR and CD28 signaling. The CTLA-4 protein thus acts as a negative 
regulator of T cell activation (15). Another inhibitory receptor is programmed cell death-1 
(PD-1), which inhibits T cell proliferation and cytokine production.  
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Towards the end of the immune response, most antigen-specific T cells die. However, in the 
presence of IL-7 a small percentage develops into memory T cells that provide long-lasting 
immunity. Although memory T cells proliferate less, their activation threshold is lower than 
that of primary T cells, resulting in a greater effector response (16). There are two types of 
memory T cells: effector memory T cells (TEM) and central memory T cells (TCM). TEMs 
migrate to the inflamed peripheral tissues and display immediate effector function; they are 
characterized by high expression of CD44 and the lack of CD45R0, CCR7 or CD62L 
expression. TCMs home to T cell areas of secondary lymphoid organs and provide reactive 
memory by proliferating and differentiating into effector cells in response to inflammatory 
processes. TCMs express CD44, but also CD45R0, CCR7 and CD62L (17).  
B cells provide the humoral (antibody) mediated adaptive immune response. They recognize 
antigens through their B-cell receptor (BCR), which is a membrane-bound form of 
immunoglobulin (Ig). Fully differentiated B cells become plasma cells, which is when they 
secrete soluble Ig (antibody) of the same antigen specificity as their BCR. Upon antibody-
pathogen binding, other cells and molecules are recruited to destroy the pathogen.  
B cells develop in the bone marrow from pro-, pre- and immature to mature B cells through 
different stages of V (variable), D (diversity) and J (joining) gene recombination of the Ig 
heavy and light chain, which will form the BCR. As with T cells, B cells undergo positive 
and negative selection processes to get their required specificity. Positive selection requires 
the pre-BCR and BCR to bind to their ligand. B cells that survived the positive selection 
process are immature B cells expressing IgM. IgM is the first antibody class secreted by 
activated B cells and is produced upon B cell activation by microbial antigens alone, without 
T cell help. Negative selection is the process where immature B cells binding to self cell-
surface antigens are removed from the repertoire, through clonal deletion, anergy, receptor 
editing or ignorance. The immature B cells that survive will migrate from the bone marrow to 
the spleen where they become mature B cells, co-expressing IgM and IgD. B cells mature in 
follicles in the spleen, they transition from T1 B cells to T2 B cells into follicular B cells or 
marginal zone B cells depending on the activating signals provided by other cells in the 
follicles. These mature B cells can then be activated to secrete antibodies (4). 
Antibodies bind to different antigens by recognizing specific epitopes with their antigen-
binding or variable (V) region. The constant (C) region exists in five different forms, called 
isotypes, and engaging of each one results in different effector mechanisms. Once the BCR 
recognizes and binds to a specific epitope on an antigen, the B cell gets activated, leading to 
clonal expansion and antibody production. Five different classes of antibodies are known: 
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IgM, IgD, IgG, IgA and IgE. IgM is present in the blood stream as a pentamer after initial B 
cell activation. To increase the affinity and variety of antibodies, B cells undergo somatic 
hypermutation and class switching with the help of T cells in peripheral lymphoid organs. 
When activated, the BCR internalizes and degrades the antigen to present it on its MHC class 
II molecules to T cells. T cells then upregulate CD40L on their surface and bind to CD40 on 
B cells. This co-stimulation together with T cell cytokine secretion stimulates the B cells and 
induces B cell proliferation, class switching, and affinity maturation. The latter, as the name 
implies, is a process to increase antibody affinity to target antigens in order to more 
effectively eliminate infections. Affinity maturation occurs by somatic hypermutation of 
proliferating B cell V genes in germinal centers in lymphoid follicles. Eventually, B cells will 
differentiate into long-lived plasma or memory B cells.   
IgA antibodies are dimers, whereas IgE and IgG are monomers and these antibodies are 
therefore smaller compared to IgM. IgA-secreting plasma cells are predominantly found in 
the lamina propria, just below the surface epithelia of skin and mucosa. IgA is secreted as a 
dimer in the lamina propia and transported across the epithelium of the gut, the respiratory 
epithelium, the lactating breast and various other glands. IgA antibodies protect epithelial 
surfaces from infectious agents and are also very important in regulating the gut microbiota 
(18, 19). IgE is mainly bound to receptors on mast cells, found just beneath epithelial surfaces 
of the skin and mucosa. Upon antigen binding, mast cells release chemical mediators such as 
histamine that can induce processes such as sneezing, coughing and vomiting, to eliminate 
the pathogen. IgE levels are elevated during allergic reactions. For the scope of this thesis, 
IgG and its effector functions will be discussed in more detail.  
IgG antibodies are found in the blood and in the extracellular fluid. It is their high affinity for 
antigen and their ability to diffuse easily throughout the extracellular fluid that make IgGs the 
primary antibodies to neutralize toxins in tissues. IgG antibodies are subdivided into IgG1, 
IgG2, IgG3 and IgG4 in humans, named by decreased order of abundance in the serum. Mice 
don’t have IgG4 but have IgG1, IgG2a, IgG2b and IgG3. Each IgG molecule consists of two 
identical class γ heavy (H) chains and two identical light (L) chains that can be either κ or λ. 
The two heavy chains are linked to each other and each light chain is linked to one heavy 
chain by disulfide bonds, resulting in a Y-shaped antibody. The N-terminal parts of the two H 
and L chains are the variable region (VH and VL), whereas the C-terminus is constant. 
Through simultaneous binding of two identical antigens by both of the N-terminal parts, the 
total antibody-antigen interaction strength is increased, resulting in a higher avidity. The N-
terminal region is also called the F(ab’)2 fragment, whereas the constant region (CH2 and 
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CH3) is named the Fc fragment. The Fc part defines the IgG isotype and interacts with 
effector molecules. Class switching occurs in the presence of cytokines produced by T cells. 
For example, B cell activation in the presence of IL-4 will induce switching to IgG1 and 
IgGE, but inhibits switching to IgM, IgG2a and IgG3. IFN-γ induces IgG2a and IgG3, TGF-β 
induces IgG2b, and IL-21 induces IgG1 and IgG3 (4, 20). These different isotypes are 
specialized to function in different compartments of the body. All four isotypes of IgG are 
important for pathogen neutralization, whereas IgG1 and IgG3 are also important for 
opsonization, NK cell cytotoxicity, activation of the complement system and to a lesser 
extend sensitization of mast cells. IgG2 can act as an opsonin in the presence of the right Fc 
receptor.  
1.1.3 Fc gamma receptors 
Antibodies binding to smaller pathogens neutralize the pathogen and protect the body 
against infection. However, they need help to destroy the pathogen. One way is by antibody-
dependent cellular phagocytosis through Fc gamma receptors (FcγRs) on effector cells 
expressing all FcγRs. Humans express six different FcγRs, including the high affinity 
activating FcγR1, the low affinity activating FcγRs FcγR2A, FcγR2B, FcγR3A and FcγR3B, 
and the low affinity inhibitory FcγR2B. FcγR1 and FcγR2B are also present in mice, whereas  
 
 
Figure 1 Mouse and human Fc gamma receptors (FcγRs). Yellow: high affinity FcγR. Red: inhibitory FcγR. Green: 
low/medium affinity activating FcγRs. Indicated which antibody isotype can activate the FcγR. The ITAM and ITIM 
motifs are indicated in green and re, respectively. The antibody isotypes that can activate the individual FcγRs are listed. 
For the human FcγRs, the different haplotypes are listed. Mouse FcγRI can also bind IgG2b and IgG3 at low affinity. 
Adapted from (21). 
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mouse FcγR4 is the orhologoue of human FcγR3A and mouse FcγR3 is the orthologue of 
human FcγR2A (Figure 1). In both human and mice, the FcγR genes are clustered in close 
proximity on chromosome 1 (22, 23). Polymorphisms of the FcγR gene cluster in mice have 
been studied in paper I. 
Antigen:antibody complexes, also called immune complexes, can be cleared by FcγRs alone 
or with help of the complement system. Complement can bind to the Fc parts of antibodies in 
immune complexes after which they bind to the complement receptor CR1 on phagocytes and 
together with the FcγR induce phagocytosis. However, mice deficient in the classical, 
alternative or mannose-binding lectin (MBL) pathway of the complement cascade showed 
unchanged antibody activity (24). Moreover, although C5a was found to be important in a 
model for autoimmune haemolytic anaemia, C5a acted as a second messenger by 
upregulating activating FcγRs rather than directly in cytotoxic reactions (22, 25). Here I will 
further describe the function of FcγR specific mechanisms. 
When binding to immune complexes, FcγRs get activated and can trigger activation of innate 
effector cells and regulation of B cells (23, 26). B cells only express the inhibitory FcγR2b 
that regulates activating signals transduced by the BCR and delivers apoptotic signals to 
plasma cells (23). Mouse NK cells only express the activating receptor FcγR3 that is involved 
in ADCC, leading to NK cell degranulation, cytokine production and target cell apoptosis 
(23). Some effector cells, such as monocytes and macrophages, express all four FcγRs and 
the net signaling outcome is determined by the ratio of activating vs. inhibitory FcγR 
expression on the cell surface. Engagment of FcγR in these cells results in the release of 
immune modulators that are cytotoxic and/or (pro-) inflammatory and in phagocytosis.  
Mouse and human FcγRs differ in their binding affinity. Whereas in humans IgG1 and IgG3 
antibodies are more pro-inflammatory, in mice this is the case for IgG2a and IgG2b, indicated 
in vivo. This difference seems to be caused by the medium-affinity FcγR4, which selectively 
interacts with these isotypes. On the other hand, IgG1 selectively binds to FcγR3, which has 
been demonstrated in mouse models using FcγR3 knockout (KO) mice that showed 
abrogated antibody activity. Moreover, the activity of IgG2a and IgG2b was not altered in 
these KO mice. Furthermore, using FcγR2b KO mice, it has been shown that FcγR2b 
negatively regulates the activity of IgG1 when co-expressed with FcγR3 on the same effector 
cell (21, 23, 27).  
Activating FcγRs consist of a ligand binding α-chain and a signal-transducing adaptor 
molecule, containing immunoreceptor tyrosine-based activator motifs (ITAM) in its 
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cytoplasmic domain. In monocytes and macrophages, this adaptor molecule consists of two γ-
chains that are involved in downstream signalling and the assembly of cell-surface transport 
of the respective α-chain. Upon immune complex binding, activating FcγRs crosslink and 
induce phosphorylation of the ITAM motif by SRC kinases. This generates a docking site for 
SYK that in turn activates various downstream targets, including the linker for the activation 
of T cells (LAT) and phosphoinositide 3-kinase (PI3K). PI3K is responsible for the 
recruitment of membrane molecules, which leads to an increase in intracellular calcium levels 
and activation of further downstream signalling events (e.g. ERK, JNK and p38), and 
eventually to cell activation (e.g. ADCP, ADCC, oxidative burst and cytokine release) (23).  
The inhibitory FcγR2b exists in two forms: FcγR2b-1, solely expressed on B cells, and 
FcγR2b-2, expressed on all phagocytes. On B cells, FcγR2b functions as a checkpoint of 
humoral tolerance. During peripheral B cell development FcγR2b 1) inhibits the activation 
and expansion of autoreactive B cells into IgG positive plasma cells, 2) excludes autoreactive 
IgG positive B cells from the follicles, and 3) induces apoptosis of autoreactive plasma cells 
upon immune complex binding. It has been shown that plasma cells from autoimmune-prone 
mouse strains have reduced FcγR2b expression and are resistant to FcγR2b dependent 
apoptosis induction. The expression of FcγR2b goes together with expression of its activating 
counterpart. Moreover, the FcγR activation threshold of a cell is determined by the activating 
to inhibitory (A/I) FcγR binding ratio on a given cells. FcγR2b expression can be altered by 
cytokines such as IL-4 and IFNγ. Whereas IL-4 reduces FcγR2b gene expression on B cells, 
increased levels are found upon stimulation with IFNγ or LPS. The opposite was true for 
FcγR2b gene expression on monocytes (28). 
Signalling by FcγR2b occurs through a single α-chain, which contains an immunoreceptor 
tyrosine based inhibitory motif (ITIM) in its cytoplasmic tail. In B cells, ITIM 
phosphorylation occurs upon crosslinking of FcγR2b and the BCR followed by recruitment 
of SHIP that prevents membrane recruitment. This in turn inhibits downstream signalling 
such as proliferation and calcium flux. On innate cells, such as macrophages and neutrophils, 
crosslinking of FcγR2b decreases FcγR mediated phagocytosis, oxidative burst and cytokine 
release. On DCs, FcγR2b inhibits DC maturation and suppresses antigen internalization and 
presentation on MHC molecules to CD4 and CD8 T cells (23, 28).  
An immune response is the balance of positive and negative signals from both arms of the 
immune system. Simultaneous triggering of activating and inhibitory FcγR signalling 
pathways and therewith setting a threshold for cell activation is an example of a well-
balanced immune response. Disturbing this balance can result in the loss of tolerance and the 
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induction of autoimmune responses. The involvement of FcγR2b in autoimmune diseases has 
been shown in both mice and humans, most prominently in systemic lupus erythematosus 
(SLE) (28). For the scope of this thesis, the role of FcγR2b in rheumatoid arthritis will be 
discussed in more detail later.  
1.2 AUTOIMMUNE DISEASES 
Autoimmune diseases affect 5-10% of the world population with a high female 
preponderance. They are chronic multifactorial diseases in which the immune system 
neglects the distinction between self and non-self (29). This causes inflammation and tissue 
damage, which can be paired with severe pain, loss of function and disability. More than 
hundred human diseases are considered autoimmune, targeting nearly every tissue. They can 
be organ specific like type I diabetes (T1D) and inflammatory bowel disease (IBD) or 
systemic such as SLE, rheumatoid arthritis (RA) and multiple sclerosis (MS). Although 
affecting different organs, they all have a common denominator: a break of tolerance by 
regulatory T and B cells. Albeit the exact trigger for this remains elusive, both genetics and 
environmental factors are known to play a key role in the development of autoimmune 
diseases (30, 31) (Figure 2).  
 
Figure 2 Representation of the development of autoimmune diseases. Showing the involvement of genetics (yellow), 
environmental factors (green) and epigenetics (blue). Disease development (initiation, progression, remodelling) depends 
on interaction between intrinsic (red) and extrinsic (green) mechanisms. Adapted from (32).  
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Despite the numerous treatments that are available for various autoimmune diseases, none of 
them cures from disease. It is therefore very important to gain a more complete understanding 
of the mechanisms behind these different autoimmune diseases. Since the genetic and 
environmental background is easily controlled in mice, candidate genes causing a particular 
disease phenotype can be identified using mouse models of human diseases (33). These 
mouse data together with data from genome-wide association studies (GWAS) and statistical 
linkage analysis in humans can be used to develop new drugs and to stratify patients into 
groups for better treatment approaches (34).  
One of the most successful treatments of the past decade is the use of therapeutic antibodies 
(IgG monocloncal antibodies) (35). They have so far been used in the treatment of SLE, MS 
and RA.  
In the present thesis I studied the role of genetic factors and a single environmental factor on 
the development of disease in mouse models of MS, IBD and RA. A description of these 
diseases will be given here with the main focus on RA.  
1.2.1 Multiple sclerosis 
Multiple sclerosis is among the most common causes of neurological disorders in 
young adults, arising between early and middle adulthood. Women are twice as likely to be 
affected than men. MS is characterized by inflammation, focal demyelination and axonal 
damage of the central nervous system (CNS) (36, 37). Many clinical symptoms for MS have 
been described and most MS patients develop one or more of these symptoms, including 
sensory and motor problems ranging from muscle spasms to partial paralysis, difficulties in 
coordination and speech, visual disturbances, cognitive impairment, depression, pain and 
fatigue (38). Even though the exact etiopathogenesis of the disease is complex and still has to 
be clarified, it is suggested to be T-cell mediated (36). CD4+ Th1 and Th17 T cells specific 
for myelin have been shown to play a role in the initiation of MS (39, 40). Moreover, genetic 
and environmental factors are involved. Since there is no cure for MS, the available 
treatments aim at managing MS symptoms (e.g. physical therapy), speeding up the recovery 
from attacks (e.g. corticosteroids) and slowing disease progression (e.g. beta interferons or 
ocrelizumab (anti-CD20)).  
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1.2.2 Inflammatory bowel disease 
Inflammatory bowel disease is an overarching term for disorders such as ulcerative 
colitis and Crohn’s disease that are chronic relapsing disorders of the gastro-intestinal tract. 
Since the mid-twentieth century, the incidence of IBD has increased dramatically and has this 
been linked to a westernized lifestyle. Alterations of the microbiota, exposure to antibiotics, 
diet, smoking and lack of vitamin D have emerged as modifiers of systemic and intestinal 
immunity. IBD patients are usually diagnosed at young age (15-35 years old) and men and 
women are equally affected (41). As nicely reviewed by de Souza & Fiocchi, IBD is 
triggered by 1) a dysfunctional immune response, 2) the environment, 3) the genetic 
make-up and 4) the gut microbiota (42). One of the earliest signs of intestinal 
inflammation in IBD is the infiltration of the gut mucosa and epithelium by neutrophils. 
However, the immunological trigger of IBD is still unclear since many abnormalities 
exist in both innate and adaptive immunity (42). Current treatment consists of classic 
anti-inflammatory drugs, immunosuppressive drugs and biological treatments such as 
anti-TNF (43). 
1.2.3 Rheumatoid arthritis 
Rheumatoid arthritis is a chronic inflammatory disease characterized by circulating 
levels of autoantibodies against the Fc part of IgG, called rheumatoid factor (RF) (although 
not specific for RA) (44), antibodies against joint-specific proteins (45) and citrullinated 
autoantibodies or ACPAs (specific for RA) (46). Patients have inflammation in the articular 
joints, which can lead to joint deformation. Disease symptoms include swelling, stiffness and 
pain in multiple joints, which often starts in wrists, hands and knees, and more general 
symptoms including fever, weight loss and fatigue. RA patients have a reduced quality of life 
with a shorter life expectancy compared to the general population (47). Moreover, patients 
can suffer from systemic immune responses such as infections and cardiovascular diseases, 
which are common co-morbidities and have been shown to increase premature death in RA 
patients (48). RA affects approximately 0.5-1% of the world’s population with a higher 
prevalence in native-American populations and in North European and North American 
countries (49). Disease onset is around 30-60 years of age with a two to three times greater 
incidence in women compared to men (50). Both genetic and environmental factors 
predispose individuals to RA and influence the disease outcome (30, 51). However the exact 
cause has yet to be determined. Although various treatments are available, due to the 
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complexity of the diseases, no cure has been found to date (34, 52, 53).  
As described by Holmdahl et al., epidemiological and genetic analyses, together with clinical 
observations, suggest that RA pathogenesis can be divided into three distinct stages: 
autoimmunity, subclinical arthritis and clinical arthritis (54). RA patients are diagnosed using 
classification criteria, which is a 1-10 scoring system, described by the American College of 
Rheumatology and European League Against Rheumatism (55). A person is classified as an 
RA patient when reaching a score of 6 (out of 10) or higher (Table 1).  
Table 1 Rheumatoid arthritis classification criteria. The scoring is based on the number and site of joints involved 
(score 0 to 5), serological parameters (score 0 to 3), elevated acute-phase response (score 0 or 1) and symptom duration 
(score 0 or score 1). RF: rheumatoid factor, CCP: cyclic citrullinated peptide, CRP: C-reactive protein, ESR: erythrocyte 
sedimentation rate.  
Criteria Points 
A) Joint involvement (0-5) 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
> 10 joints (at least 1 small joint) 5 
B) Serology (at least one test result is required) (0-3) 
RF (-) and anti-CCP (-) 0 
Low titer RF (+) or low titer anti-CCP (+) 2 
High titer RF (+) or high titer anti-CCP (+) 3 
C) Acute-phase reactants (at least one test result is required) (0-1) 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D) Duration of symptoms (0-1) 
< 6 weeks 0 
≥ 6 weeks 1 
 
Patients can be divided into serological positive or negative groups (RF and ACPA). Both 
ACPA and RF positive patients are at a higher risk of developing a more aggressive form of 
arthritis, leading to more joint damage (56, 57). For treatment purposes patients are stratified 
based on their serology or genetics. 
1.2.3.1 Pathogenesis  
As RA is a complex autoimmune disease, or rather disorder, there are numerous molecular 
mechanisms underlying RA. Altered post-transcriptional regulation by environmental factors, 
susceptible genes and epigenetic modifications could lead to self-protein modification, 
resulting in loss of self tolerance and subsequent autoimmunity presented as autoantibody 
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production (31). Moreover, dendritic cells could present these altered self-peptides and 
activate T and B cells. It is however suggested that this process occurs outside of the joint, 
either at the side of “stress”, in secondary lymphoid tissues, in the bone marrow or in the lung 
(58, 59) unknown signal would then be required to relocate the inflammation to the joint 
where synovitis is initiated (60). Synovitis is inflammation of the synovial membrane and is 
the first clinical sign of RA (61). This inflammation is initiated and perpetuated by cells from 
the innate and adaptive immune system, both resident and infiltrating, and their interaction 
with synovial fibroblasts, chondrocytes and osteoclasts.  
A healthy synovium comprises mainly of macrophages and fibroblast-like synoviocyte 
(FLS). During on-going joint inflammation, the lining layer of the synovium thickens paired 
with infiltrating lymphocytes (CD4+ and CD8+ T cells, B cells, plasma cells), monocytes, 
macrophages, mast cells, NK cells and dendritic cells. Neutrophils mainly reside in the 
synovial fluid where they secrete prostaglandins, proteases and ROS. Macrophages are potent 
effector cells during synovitis, they are activated via different routes including direct T cell 
contact, the ligation of TLRs and binding of immune complexes to FcγRs. Upon activation 
macrophages release a large amount of cytokines such as IL-6, TNF and IL-1, chemokines, 
reactive oxygen and nitrogen, as well as matrix-degrading enzymes (e.g. MMP). Cytokines 
such as IL-1 and TNF can activate FLS, which in turn produce high levels of matrix-
degrading enzymes, adhesion molecules, chemokines and cytokines, including high levels of 
M-CSF. M-CSF in turn induces macrophage differentiation from monocytes, creating a more 
inflammatory environment, and induction of osteoclastogenesis (formation of osteoclasts). 
Furthermore, MMPs and cytokines such as IL-1 and TNF-a will affect chondrocytes by 
degrading cartilage. They can also increase osteoclast numbers and breakdown osteoblasts. 
Moreover, TNF mediates leukocyte activation, endothelial angiogenesis and nociception and 
is suggested to be involved in processes of the central nervous system, such as depression and 
fatigue. Secreted by multiple cells, IL-1, TNF-a and IL-6 are abundantly present in RA 
synovium and have all been targeted for treatment (60).  
Another cytokine that is present in RA synovium and activates macrophages, FLS and 
osteoclasts to promote the release of additional inflammatory mediators, is IL-17, produced 
by activated T cells. Although frequencies of Th17 cells in blood are similar between healthy 
controls and pre-RA patients, they are elevated in blood and synovial fluid of patients with 
established disease (14). Despite the great success of blocking IL-17 in a mouse model of RA 
(collagen-induced arthritis, CIA), to date IL-17 targeting therapeutics have not been effective 
in patients with established RA (60). Additional cytokines produced by CD4 T cell subsets 
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are also present in serum and RA synovium. Both Th1 cells and Th1 cytokines, such as IFN-
y, IL-2 and TNF-a, are elevated in RA patients. On the other hand, involvement of Tregs in 
RA is not as clear (62). Given that Tregs are involved in the suppression of autoreactive T 
cells, one explanation is that the functionality of Tregs has been altered in RA. This has been 
shown by defective CTLA-4 regulation using KO mouse models (63–65). Another reason 
could be the responsiveness of T cells to Treg mediated suppression. Furthermore, it has to be 
noted that T cell subsets can be plastic and their interactions complex. An imbalance between 
pro- and anti-inflammatory subsets, Th17 and Tregs for example, is often considered 
responsible for disease development (60, 66).  
Clearly, autoantibodies, present in serum far before clinical disease onset, are a hallmark of 
RA, suggesting a major involvement of B cells. B cells are indeed present in RA synovial 
tissue in close contact with T cells, which are believed to provide help to B cells to produce 
autoantibodies (67). In case of RF and ACPA, natural B cells are activated through germ-
line-encoded BCRs (68). The initial low avidity and titers of these antibodies increase with 
time due to germinal centre selection and the help of T cells (69). However, correlation of 
joint destruction with low-avidity ACPAs has been reported (70). ACPAs are highly specific 
for RA (up to 98%), albeit not present in all patients (up to 77%), whereas RF can also be 
found in other autoimmune diseases. Even though there is no clear proof that RA 
autoantibodies are pathogenic in humans, studies in mice clearly show that epitope specific 
anti-collagen type II (CII) antibodies can induce arthritis. Furthermore, it has been shown that 
CII-specific B cells can give rise to antibodies that attack the cartilage matrix without any 
clinical signs of arthritis (71–73). Increased pain has been reported as well (74). Moreover, 
some specific ACPAs can give rise to activated osteoclasts with consequent bone destruction, 
as demonstrated in both RA and animal models for arthritis (59, 75, 76). Despite the absence 
of ACPAs in animal models for RA, RFs are found in several animal models including CIA 
(77). Here, T cells activated by CII, provide help to cross-reactive B cells, with consequent 
antibody production.  
Furthermore, it has been demonstrated that increased numbers of B cells are present in joint 
tissue and in draining lymph nodes of patients with early RA (78, 79). Furthermore, aside 
from its role in antibody production, synovial B cells also contribute to disease progression 
by secretion of pro-inflammatory cytokines such as IL-6 and TNF. The most prominent proof 
of B cell contribution in RA is the successful therapeutic depletion of CD20+ B cells using 
Rituximab.  
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Both the complement system, particularly component C5, and the FcγRs get activated by 
anti-CII antibodies, initiating the inflammatory response in RA (80, 81). In humans, 
polymorphisms have been described within the coding sequences of FcγR3A and FcγR2B in 
association to different autoimmune diseases. The different forms are thought to alter ligand 
binding affinity and receptor-mediated effector functions (82–84). It has been shown in mice 
that lacking the signalling subunit of the activating receptors FcγR1 and FcγR3 protects from 
arthritis, whereas mice deficient in the inhibitory receptor FcγR2b develop a more severe 
disease (80, 85–87). Furthermore DBA/1 FcγR3 KO mice are protected from CIA despite 
producing similar amounts of anti-CII mAbs as control mice (88). Moreover, when inducing 
arthritis in mice using single anti-CII mAbs, mice that lack FcγR2b show enhanced disease 
whereas mice lacking FcγR3 do not develop arthritis (89, 90)ince FcγR bearing cells, 
including macrophages, neutrophils and NK cells, are a prominent feature of rheumatoid 
synovium and synovial fluid, the binding of autoantibodies such as RF to these cells is likely 
to contribute to the inflammatory process in RA (91). Therefore extensive research on the 
role of the various FcγRs on different cell types in arthritis has been conducted in both mice 
and humans (92). Polymorphisms in FcγR3a in RA patients can be used to predict treatment 
response to for example rituximab (anti-CD20) (34, 93).  
1.2.3.2 Genetics of RA 
It has been suggested from twin studies that the heritability of RA is approaching 
65%, which means that in an RA patient up to 65% of the disease could be allocated to 
genetics (94). Using Genome Wide Association Studies (GWAS) more than 100 genetic risk 
loci have been associated with RA, also indicating the contribution of environmental factors 
on disease development and progression (34). Despite large efforts in identifying genetic 
factors affecting RA, less than 50% of the estimated heritability can be explained by 
previously identified risk alleles. Moreover, only 16% of the total RA susceptibility can be 
explained (95–98). This is depicted as “variance explained” in Figure 3 and represents the 
sum of genetic variance and environmental variance.  
The first identified risk genes in RA were the major histocompatibility complex (MHC) 
genes, with strong association to human leukocyte antigen (HLA)-DRB1*04 (99). To date, 
the strongest genetic association among autoantibody-positive European RA patients still 
remains the HLA-DRB1 alleles (100–103).  
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Another strongly associated risk gene, which was initially found in T1D, is the protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) (104, 105) in which a non-synonymous 
coding SNP (R620W) causes T cell hyporeactivity (106, 107). Moreover, R620W has been 
linked to the presence of RF and anti-cartilage specific antibodies in RA patients (104, 108). 
The importance of T cells in RA development is also supported by genetic associations with 
the CTLA4 gene (109, 110) and the signal transducer and activator of transcription 4 
(STAT4, (111)). CTLA-4 deletion in adult mice has been shown to result in more severe 
arthritis development compared to control mice (63). On the other hand, STAT4 is a 
transcription factor essential for the development and maturation of Th1 and Th17 cell 
populations (112).  
 
 
Figure 3 RA genetic risk loci. Odds ratios for the risk loci are presented in a chronological order of discovery. Data of 
Caucasian (white) and Japanese cohort are shown (98). 
 
A number of genetic studies made it possible to stratify patients as being ACPA positive or 
ACPA negative with stronger genetic associations in the ACPA+ subgroup (113, 114). A few 
loci, such as TNFAIP3, STAT4, IL6ST and PTPN22 have been associated to RA 
susceptibility independent of antibody titers (97, 115). Among others, CD28, CTLA-4, 
CD40, HLA-DRB1*15, HLA-DRB1*03, HLA-DRB1*1, C5, FCΓR2B and FCΓR3A have 
been mainly associated with ACPA+ disease (34, 93, 116–119). However, due to genetic 
heterogeneity, environment variability, gene-gene or gene-environment interactions and 
various life styles, it has been difficult to find other causative genes within the human 
population.  
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1.2.3.3 Environmental factors 
Over the years, several environmental factors have been associated with the risk of 
developing RA (120) with smoking being the most prominent one (121, 122). Smoking has 
been shown to enhance the risk in serologic positive patients who carry the HLA-DRB1 
shared epitope (SE) alleles or PADI4 polymorphisms (123–126). In patients carrying the 
HLA-DRB1 susceptible allele, increased production of anti-CCP (cyclic citrullinated peptide) 
antibodies and T cells reacting to citrullinated proteins have been described (127, 128).  
The geographical prevalence of RA and other autoimmune diseases has generated the 
hypothesis that vitamin D levels are an important risk factor. In RA, several epidemiological 
studies show an association between low levels of circulating vitamin D and an increased risk 
or severity of arthritis (129–131). However, there has been some conflicting data (132–134). 
Moreover, based on data from healthy individuals with high exposure to sunlight and vitamin 
D deficiency, lack of vitamin D might rather be a consequence of chronic inflammation than 
a cause thereof (135). Another theory is that cellular infections by bacteria or viruses like 
Epstein-Barr virus (EPV) are the underlying cause for RA (136). EPV is a ubiquitous virus 
with 95% of the world’s population being infected. It has been found in sera and in synovial 
tissue of RA patients (137, 138). 
Another broadly studied environmental factor is eating habits. However, due to the common 
issue of inaccuracies in assessing dietary intake, evaluating the effect of diet on RA is 
difficult. Through a nested case-control design in the Västerbotten Intervention Program 
(VIP) cohort in Sweden, a significant association was found between protein consumption 
and an anti-CCP-positive disease or smokers (odds ratio (OR) of 1.40 and 1.80 respectively). 
However, associations were no longer significant when the data was adjusted for sodium 
intake (139). In this regard, recent studies in animal models and on human cells ex vivo have 
demonstrated the importance of sodium in the induction of pathogenic Th17 cells (140, 141). 
Since Th17 cells are suggested to be a key player in the early pathogenesis of RA (142), the 
role of dietary sodium in the disease course of RA in the VIP cohort has been re-evaluated 
(139). Stratifying patients based on their smoking status at the time of the examination 
showed that sodium intake more than doubled the risk for RA among smokers. This was not 
observed among non-smokers. More than 50% of the increased risk of developing RA from 
exposure to smoking or high dietary salt intake was due to interactions between the two. The 
risk was further increased for the development of anti-CCP-positive and/or HLA-SE–positive 
RA (139). On the contrary, we have shown in mouse models for RA, that elevated levels of 
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sodium, provided in drinking water, did not affect the development of arthritis. Thus even in 
an environment controlled setting, this single environmental factor does not have an impact 
on arthritis development (Paper III) (143).  
1.2.3.4 Current treatment strategies 
The most commonly used treatments for RA are non-steroid anti-inflammatory 
drugs (NSAIDs) that reduce pain; disease-modifying anti-rheumatic drugs (DMARDs) such 
as methotrexate that reduce structural joint damage progression; and corticosteroids that 
relieve acute symptoms. The problem with these drugs, and with many drugs in general, is 
the developed drug tolerance in many patients. During the last years, biologic agents have 
been introduced as treatment (53). These include monoclonal antibodies and recombinant 
proteins targeting pro-inflammatory molecules. The first and most successful biological agent 
used to treat RA is a monoclonal antibody against TNFα, (144). Anti-TFNα agents, such as 
etanercept are now widely used for RA treatment. Use of anti-IL-6 (e.g. Tocilizumab), 
CTLA-4 fusion proteins (e.g. Abatacept) or anti-CD20 monoclonal antibodies (e.g. 
Rituximab) have been very effective. More recently, small molecule inhibitors of the JAK 
pathways have been very successful in the treatment of early RA (145, 146). However, 
targeting cytokines such as IL-1, IL-17, IL-21 or IL-22 showed less effective.  
To improve the safety and efficacy of drugs used for treating RA patients, pharmacogenetics 
and pharmacogenomics analyses have been adopted from GWAS data trying to develop 
personalized treatment strategies (147, 148). However, there is still a gap to be filled in the 
full understanding of RA pathogenesis for which basic research is fundamental.  
1.3 ANIMAL MODELS FOR AUTOIMMUNE DISEASES 
Using mouse models and different mouse strains, the observed phenotypes and linked 
genes can be further investigated in an environmentally and genetically controlled manner 
(149–156). However, due to the complexity of autoimmune diseases, no single animal model 
can cover the entire spectrum of the heterogeneous human disease. Nevertheless, the 
individual models are very useful to study one or more aspects of the corresponding human 
disease and give the possibility to knock down or enhance the expression of genes. Below I 
will briefly describe the animal models used in papers I, II and III.   
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1.3.1 Arthritis models 
There are many different mouse models to study RA that are either spontaneous (e.g. 
TCR transgenic K/BxN mice and SKG mice) or induced. Well-studied induced mouse 
models for RA are collagen-induced arthritis (CIA), collagen antibody-induced arthritis 
(CAIA) and glucose-6-phosphate isomerase (GPI)-induced arthritis. These models touch 
upon individual stages of disease development, mostly covering the clinical phase of arthritis.  
CIA, in which mice are immunized with the major articular cartilage protein CII, is 
dependent on both T cells and APCs such as B cells (157). B cells are important for antibody 
production against CII (158). CIA resembles several features of RA like pannus formation in 
the synovium, bone erosion, immune cell infiltration, MHC dependence and engagement of 
both cellular and humoral responses.  
Autoantibodies have long been considered to be involved in the pathogenesis of RA. Using 
CAIA, in which epitope defined anti-CII monoclonal antibodies are injected into mice, the 
disease dependency on joint specific antibodies (e.g. CII) can be studied. It further allows 
studying the effector phase of arthritis without involving the priming phase. CAIA is 
characterized by acute infiltration of neutrophils and macrophages (6). It moreover requires 
the involvement of complement components and FcγRs (159, 160).  
1.3.2 Experimental autoimmune encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is the extensively used animal 
model for MS having similar clinical, immunological and genetic features as seen in MS 
(161). Disease is induced in susceptible mice with CNS proteins or peptides such as myelin 
oligodendrocyte glycoprotein (MOG) or myelin basic protein (MBP). The disease 
development can either be acute progressive, chronic or remitting, depending on the mouse 
strain used, and is Th1 and Th17 dependent. The model is used to gain more insight into the 
pathogenesis of the disease, as well as for pharmacological and genetic studies.  
1.3.3 Dextran sulphate sodium-induced colitis 
Dextran sulphate sodium (DSS)-induced colitis is the most widely used animal model 
to study IBD and is fast, simple, reproducible and easily controlled. DSS is administered 
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through drinking water and it affects disease severity depending on its molecular weight 
(ranging from 5 to 1400 kDa) and administration dose (1.5 – 5%). The disease can be acute, 
chronic, and relapsing based on the administration dose and frequency. Administering 40-50 
kDa DSS in drinking water, most closely resembles human ulcerative colitis (162). 
Characteristics of the disease are weight loss, faecal and rectal bleedings, splenomegaly, 
decreased colon length, epithelial erosion and immune cell infiltration in the colon. 
Furthermore, gut microbiota is a key determinant of the development and severity of colitis, 
with exacerbated colitis in mice treated with antibiotics (163, 164). Unlike in human disease, 
T and B cells are not required for DSS-induced colitis disease development. Nevertheless, T 
cells are amongst the pro-inflammatory infiltrating cells in the colon, together with 
macrophages (chronic disease) and neutrophils (acute disease) in mice. 
1.4 STUDYING GENETICS AND GENE FUNCTION IN ANIMAL MODELS 
Identifying quantitative trait loci (QTLs) in family linkage studies was an initial step 
in identifying and sequencing genes in the susceptibility to a particular disease (165). 
However, this approach did not generate many linked loci. The only conclusively linked 
locus identified in RA was the MHC. From the past decade, genetic mapping of complex 
multifactorial diseases, such as RA, has been done by GWAS in which large cohorts, 
including patients and healthy controls, are genotyped with whole genome sequencing using 
coding information from single nucleotide polymorphisms (SNPs). This makes it possible to 
identify genes and/or proteins likely to regulate the observed phenotype (166). With GWAS, 
new disease loci are identified after which the risk effect in a particular locus can be fine 
mapped in order to quantify the heritability and to narrow down which variants/genes in that 
locus are relevant (167). However, in complex autoimmune diseases it is the involvement of 
multiple causal variants in many disease-associated loci (168), often working in concert. 
Moreover, it is not only the common and low-frequency variants (allele frequency of 0,5 – 
5%) that account for the genetic heritability of a disease. Albeit poorly studied, rare variants 
(with an allele frequency of <0,5%) and copy number variations also contribute to complex 
autoimmune diseases. In RA, copy number variants have been reported for the MHC region, 
FCΓR3A, FCΓR3B and others (169–171).  
Human genome studies require large cohorts due to a large number of variables. Therefore, 
utilization of animal models is essential. In experimental models, environmental factors and 
genetic backgrounds can easily be controlled, reducing the variability and thus the number of 
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animals used. Moreover, animal models allow studying the molecular pathways and the role 
of candidate genes leading to disease development (33). In order to identify disease-
associated loci, several approaches can be used after which the contribution of the candidate 
gene(s) can be verified using KO, knockin (KI) or transgenic mouse models and gene 
silencing methods (172, 173). Partial advanced inter-cross (PAI) lines, F2 crosses, 
heterogeneous stock (HS) mice or congenic mice are models used to identify disease-
associated loci and to map susceptible elements and gene(s) (151, 156, 172, 174). A PAI 
breeding strategy is used to investigate genetic interactions between QTLs on two congenic 
strains, created on the same genetic background, to identify the disease phenotype associate 
genes. F2 crosses are used for linkage analysis, in which a particular trait is linked to the 
identified locus. In this thesis, congenic mice have been used to study the genetic effect on 
arthritis development in mice and the functionality of these genes. – 
1.4.1 Congenic mice 
Congenic mice are inbred mice that carry a defined 
part of a genome (the congenic locus) of one mouse strain 
(donor) introgressed into another mouse strain (receiver) 
(175). Thus the background genome of the congenic mice 
is identical to that of the receiver. Initially, the donor 
strain, with a different genetic signature, is crossed with 
the receiver strain resulting in F1 mice (Figure 4). These 
F1 mice, 50% identical to the respective donor, are further 
backcrossed to the receiver with the help of marker-
assisted selective breeding until 99,9% of the donor 
genome material outside of congenic locus is eliminated 
(172). This is usually achieved with 10 backcrosses. The 
obtained congenic mice can then be kept in homozygous 
and heterozygous intercross breeding to prevent 
spontaneous recombinations by meiosis and to create 
littermate control mice to study the disease phenotype, 
respectively. The littermate control mice have genetic 
material identical to the receiver. So when studying the 
disease phenotype, the observed phenotypic differences 
Figure 4 The generation of congenic mice. F1: 
50% donor, N2: 25% donor, N10: <0.5% donor. 
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can be allocated to the genetic fragment obtained from the donor. However, the congenic 
fragments often consist of multiple genes and fine mapping is not as straightforward, since at 
a certain fragment size the chances of finding new recombinations will decrease. 
Nevertheless, a candidate region can be investigated in detail using several approaches: 1) 
search literature for relevant gene information and 2) assess sequencing databases for SNPs 
and transcriptional activity between congenic mice and receiver. Once one or several 
candidate genes have been found, cell specific gene and protein expression can be assessed, 
followed by functional studies.  
1.4.2 Knockout mice 
One commonly used method to verify the role of a candidate gene is the use of 
knockout mice. KO mice have mostly been generated using embryonic stem (ES) cells from 
the 129 inbred mouse strain. A null-mutation is made in the 129 ES cells, which are then 
injected into a blastocyst and implanted into the uterus of a pseudo-pregnant female. If the 
mutant gene is transferred to the offspring, the mutant gene can be bred to homozygosity to 
get a KO mouse. As with congenic mice, the obtained KO mouse should be backcrossed to 
the desired background to limit the genetic effect of the 129 background. Even so, tightly 
linked genes in the flanking region surrounding the null mutation do not separate easily and 
are often contained within the KO mice. So besides studying the effect of the knocked out 
gene, the interaction of the flanking genes will have a significant impact on the studied 
phenotype (173, 176). Therefore, several KOs have been made in the B6 mice directly. A 
relevant example is the FcγR2b KO mouse. Whereas FcγR2b129 KO mice showed high 
susceptibility to lupus, FcγR2bB6 KO mice failed to develop disease (177). This clearly 
indicates the impact of the linked genes. Nevertheless, both KO mouse models are widely 
used models to study genetic functions.  
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2 PRESENT INVESTIGATIONS 
This thesis comprises of three studies, all of which focus on various functions in the 
regulation of autoimmunity in mouse models.  
2.1 AIMS 
The overall aim of the present thesis was to investigate the effect of genetic risk loci and that 
of environmental factors on the development of autoimmune diseases in a further 
understanding of the mechanisms behind these complex diseases.  
The specific aims of the constituent papers were:  
Paper I: To identify the arthritis promoting genes in the arthritis susceptible Cia9 locus, and 
to investigate the functional effect of polymorphic Fc gamma receptor genes on immune cells 
and arthritis disease development in mice.  
Paper II: To assess the importance of the system A family of amino acid transporters as 
mediators of immune cell function and arthritis development in mice. 
Paper III: To study the effect of salt on immune cell function and on the development of 
autoimmune diseases in mouse models. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Paper I 
Immune complex receptors FcγR2b and FcγR3 alleles act in concert to regulate 
inflammation 
When the balance between FcγR2b and the activating FcγRs on the same cells is 
disturbed, this can lead to the development of chronic inflammatory or immunological 
diseases (28, 92). Polymorphisms in human FcγRs have been linked to systemic lupus 
erythematosis (SLE) and rheumatoid arthritis (RA). Moreover, with the use of various FcγR 
knockout mice, it has been shown that FcγRs are important in the downstream effector 
pathways driving pathogenesis in autoimmunity (178). However, it has to be taken into 
account that the expression and function of other FcγRs might be influenced when knocking 
out an individual FcγR (179), which is due to genetically linked genes. This effect can be 
diminished with the use of congenic mice. Previous studies have indicated the importance of 
the FcγR gene cluster (including FcγR2b, FcγR3 and FcγR4), located on the NOD.Q-derived 
Cia9 locus on chromosome 1, in arthritis development (174, 180, 181). In Paper I, we 
addressed this by using sub-congenic Cia9 mice to study arthritis susceptibility and to 
investigate the functional effect of polymorphic Fc gamma receptor genes.  
To identify the arthritis promoting genes in the susceptible Cia9 locus, CIA and CAIA were 
run in the four overlapping sub-congenic lines Cia9b, Cia9c, Cia9i and Cia9k. Cia9b spans 
the region above the FcγR cluster on chromosome 1, Cia9c covers the region below the FcγR 
cluster, containing several genes from the SLAM family, 
and Cia9i and Cia9k contain the FcγR gene cluster, 
excluding the SLAM region. Cia9b and Cia9c both 
showed no regulation of arthritis, which restricted the 
disease-regulating interval to less than 1 Mb of Cia9. 
The sub-congenic Cia9i and Cia9k loci on the other 
hand, ~2 Mb fragments, showed significant arthritis 
regulation, confirming arthritis regulation to a < 1 Mb 
interval in between the Cia9b and Cia9c locus. It was 
indeed the polymorphic FcγR gene cluster that regulated 
arthritis (Figure 5). Polymorphic FcγR2b and FcγR4 
Figure 5 Polymorphisms in the Cia9i and 
Cia9k fragment exacerbate arthritis onset 
and development of CAIA. Mice were 
injected i.v. with 4 mg of anti-CII mAbs 
cocktail on day 0 and boosted with LPS i.p. 
on day 7. Arthritis score was assessed 
macroscopically. (arthritis/number of mice). 
Significant differences between WT and 
Cia9i (*), Cia9i and Cia9k ($) and WT and 
Cia9k mice (#).  
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were contained in both Cia9i and Cia9k, whereas Cia9i mice also carried polymorphic 
FcγR3. FcγR2b gene and protein expression were downregulated in Cia9i and Cia9k mice, 
whereas FcγR3 was upregulated in Cia9i mice and downregulated in Cia9k mice compared to 
littermate control mice. No expression differences for FcγR4 were observed.  
To further investigate the role of polymorphic FcγR2b and FcγR3, FcγR-dependent functions 
on B cells, NK cells and macrophages were studied. Since elevated levels of anti-collagen 
type II (CII) antibodies were found in Cia9 mice during CIA (181) and the role of FcγR2b 
(182) has been suggested, we assessed the function of B cells in in vivo and in vitro antibody 
secretion. Despite lower expression of FcyR2b on Cia9i and Cia9k in vitro activated B cells, 
no differences in anti-CII antibody levels or in vitro antibody production by CII primed B 
cells were observed.  
For macrophages, an FcγR3 mediated mechanism was observed. With the use of antibody 
dependent cellular phagocytosis (ADCP) we studied the effect of activating FcγRs. We show 
that Cia9i macrophages, which have increased FcγR3 expression, induce significantly more 
phagocytosis compared to macrophages of WT, Cia9k and FcγR3 KO mice. The same was 
true for FcγR3 mediated Treg depletion in vivo using PC61 antibody, which has previously 
been shown to be dependent on macrophages (183). We saw increased depletion of Treg cells 
in Cia9i mice and decreased depletion in Cia9k mice compared to WT mice. We furthermore 
show that Cia9i mice have increased oxidative burst both through FcγR dependent and 
independent pathways. Previous studies in neutrophils show that both FcγR2b and FcγR3 
affect ROS production. Using FcγR3 KO mice, ROS production by neutrophils was solely 
regulated through FcγR mediated pathways (184, 185), whereas in FcγR2b KO mice the 
oxidative burst was affected after stimulation with LPS as well (186). Our results clearly 
show a major effect from FcγR3 in both settings. Although not significantly different, Cia9k 
mice show a trend towards higher oxidative burst compared to WT mice. This indicates, and 
is in line with our arthritis data, a combined role of FcγR2b and FcγR3 and points towards an 
altered activating to inhibitory (A/I, e.g. FcγR3:FcγR2b) binding ratio, which determines the 
FcγR activation threshold (28).  
We further showed the importance of NOD.Q polymorphic FcγR3 by studying antibody 
dependent cellular cytotoxicity (ADCC) by NK cells. The specific lysis by Cia9i and WT NK 
cells was linked to FcγR3 expression. Interestingly though, specific lysis by Cia9k NK cells 
was also increased compared to that of WT NK cells. Since FcγR3 expression on Cia9k NK 
cells was slightly reduced, we expected lower or equal NK cell mediated lysis. This points 
towards the involvement of other linked genes within the congenic fragment. The only gene 
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within the Cia9k fragment that has been associated with NK cell-mediated cytotoxicity is the 
activating transcription factor 6 (Atf6) (187). It is possible that without NOD.Q FcyR3, 
NOD.Q Atf6 still controls cytotoxicity. 
With our congenic mice, we were able to study the independent and additive effect of 
FcyR2b and FcyR3 on inflammation without major impact of the NOD.Q flanking region. 
Our congenic mice could provide a more physiological setting to study FcγR function. Recent 
data suggest that the activating FcγRs, FcγR4 in particular, on neutrophils in the joint mediate 
bone erosion during antigen-induced arthritis (188). Since we also showed increased arthritis 
susceptibility in a model mediated by macrophages and neutrophils, it would be interesting to 
further investigate this in our congenic mice. Furthermore, a recent study shed light on the 
involvement of FcγRs in the adaptive immune system. Through APC-mediated presentation 
of immune complexes, they show that the role of activating FcγRs is redundant (189). In line 
with this, we did not find an impact from B cells. Nevertheless, the above-mentioned studies 
have been conducted in complete FcγR knockout mice. It therefore would be interesting to 
further investigate the role of polymorphic FcγRs on adaptive immune regulation.  
In summary, we show that it is the additive effect of genetic polymorphisms in FcyR2b and 
FcyR3 that regulate arthritis severity and inflammation in our congenic mice, likely through 
macrophage-mediated mechanisms.  
  
 30 
2.2.2 Paper II  
System A amino acid transporters regulate glutamine uptake and attenuate antibody-
mediated arthritis. 
Glutamine is the most abundant amino acid in the circulation and can be used as an 
alternative energy source in actively proliferating cells. Its metabolic role in immune cell 
activation, such as macrophages and T cells, has been well-studied, demonstrating its 
importance in immune function (190–193). During an inflammatory response, immune cells 
are in high demand for intracellular amino acids that can either be generated endogenously or 
that have to be transported from the extracellular environment (194). One such transporter for 
glutamine is the system A family of amino acid transporters (members of the sodium-coupled 
neutral amino acid transporters – SNAT) (195), which is a unidirectional transporter for 
sodium ions and neutral amino acids. These transporters, existing of SNAT1, SNAT2 and 
SNAT4, were shown of importance during several T-cell activation processes (191, 196, 
197). Moreover, the genetically clustered SNAT1, SNAT2 and SNAT4, were previously 
identified in a 800 kb quantitative trait locus (Cia36) that regulated arthritis development in 
the T-cell dependent mouse model collagen-induced arthritis (152). However, the exact role 
of these SNAT proteins in arthritis development remains elusive. In Paper II, we address this 
problem by blocking the SNAT proteins during T-cell activation and proliferation in vitro 
and during T-cell dependent and T-cell independent arthritis development in vivo.  
To evaluate the role of system A proteins during T cell activation, we performed kinetic 
studies by stimulating spleen cells with anti-CD3/28 in vitro in the absence or presence of the 
amino acid analogue 2-(methylamino) isobutyric acid (MeAIB) to block the system A 
proteins. We found that Slc38a1 and Slc38a2 (corresponding to SNAT1 and SNAT2 proteins, 
respectively), as well as Mtor and Erk1 gene expression were significantly increased after 2-
hour culture and were back to basal levels after 5 and 24 hours, indicating rapid de novo 
synthesis of these proteins to supply the cell’s energy demands.  MeAIB significantly reduced 
expression of the genes after 2-hour culture, but expression levels after 5 and 24 hours culture 
did not reduce to basal level. We furthermore showed that glutamine uptake by T cells is 
dependent on system A transporters, only in the presence of Na+ in culture medium. 
Moreover, under normal culture conditions, T-cell proliferation and activation (shown as IL-2 
and IFNγ secretion) were significantly reduced when blocking SNAT proteins.  
To test if the same were true in models for autoimmunity, we administered mice daily with 
MeAIB or PBS, starting 7 days before induction of arthritis. Given the protective role of the 
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Cia36 locus in arthritis development (152) and the role of SNAT proteins in T cell activation, 
we expected an effect on T-cell dependent arthritis development when blocking SNAT 
proteins using MeAIB. Although we did not observe any significant differences in arthritis 
severity, SNAT blockage did cause a delayed disease onset in CIA. After receiving a second 
inflammatory trigger, this difference disappeared. When using the antibody-mediated arthritis 
model, we saw a significant reduction in both arthritis severity and incidence that was paired 
with decreased numbers of neutrophils and elevated levels of Ly6Clo monocytes in the blood 
when using MeAIB. The former indicates lower levels of inflammation (6), whereas the latter 
might indicate increased clearance of formed immune complexes by FcγRIV on these cells 
(198). No differences in T cells were detected. Nevertheless, in the absence of T cells in 
TCRβ KO mice, MeAIB had a less pronounced effect on CAIA disease severity, albeit 
causing a lower disease incidence. This indicates the contribution of SNAT proteins in T cells 
and innate cells such as neutrophils in CAIA disease development.  
Whereas the immune system is overly activated during an autoimmune disease, it is 
weakened in the presence of tumours. Tumours are also major consumers of glutamine, but 
they are insensitive to repression of glutamine uptake via SNAT proteins (193, 199, 200). 
Here, we show that de novo synthesis of SNAT1 proteins occurs upon effective blocking of 
system A proteins in HEK293T cells, which correlates with the proliferation status of these 
cells (Figure 6).  
 
Figure 6 System A substrates affect proliferation of immortalized cell lines. 2.5x105 HEK293T cells were seeded per 
25-cm2 culture flask in medium supplemented with different concentrations of MeAIB. After 72 hr, the total number of 
cells was assessed (a, b) and total RNA samples were collected for quantitative expression of Slc28a1 gene (SNAT1) (c). 
Adapted from (201). 
Based on our and recently published data (202), our in vitro results clearly show the 
importance of system A transporters in naïve T cell activation and proliferation. Whereas 
another amino acid transporter, system ASC, is crucial for the development of Th1 and Th17 
cells, they did not alter the levels of IL-2 and Treg cells (202). Given the IL-2 and 
proliferation signature we observed, we suggest that SNAT proteins are involved in the initial 
activation of lymphocytes. This also seems to be the case during the onset of CIA. After 
boost however, mice in the different treatment groups get equally sick. One explanation for 
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this could be the involvement of other amino acids or transporters that could have been 
activated upon elongated blockage of SNAT proteins. Moreover, T cell activation does not 
get completely hampered when treated with MeAIB. So upon a second signal, activated 
immune cells, including T cells, might have found another way to reach their energy demand 
and increase activation and disease. Nevertheless, we show a significant reduction in CAIA 
disease severity and incidence upon SNAT blockage. 
Collectively, we demonstrate that naive lymphocytes preferentially use SNAT proteins for 
the uptake of extracellular glutamine. Trans-inhibition of SNAT proteins in immortalized cell 
lines, although to a lesser extent than lymphocytes, results in a reduction of cell proliferation. 
And, in vivo administration of the SNAT inhibitor MeAIB significantly diminishes the 
severity of antibody- mediated arthritis, most likely through its effect on metabolically active 
inflammatory cells.  
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2.2.3 Paper III 
Increased salt exposure affects both lymphoid and myeloid effector functions, 
influencing innate-associated disease but not T cell-associated autoimmunity.  
Short title: Salt affects colitis but not autoimmunity 
Dietary salt, in the form of sodium chloride, has over the last couple of years been 
studied extensively as an environmental factor in several diseases (203–206). Its excessive 
intake through increased consumption of processed food, has been associated with elevated 
blood pressure, coronary heart disease and stroke (206, 207). Moreover, there is rising 
evidence that this Westernized diet can contribute to the pathogenesis of autoimmunity (203, 
206, 208, 209). Food is digested in the gut, with help of a person’s microbiome. Although the 
microbiome is relatively stable over time, its composition can be altered by various 
environmental factors, including diet, which in turn has been linked to various inflammatory 
diseases (210, 211). Moreover, studies in germ free mice show altered T-cell signatures in the 
lamina propia of the small intestine. These mice were protected from experimental 
autoimmune encephalomyelitis (EAE) and colitis (212–214). Furthermore, feeding mice a 
high salt diet (HSD) lead to induction of Th17 cells and exacerbation of EAE symptoms (140, 
141, 215, 216). However, these mouse studies have been conducted with a dramatic increase 
in dietary salt consumption. A further understanding of a more physiological increased salt 
concentration on immune cell function and the development of autoimmune disease is 
needed. In Paper III we addressed this issue by studying the effect of increased salt exposure 
on immune cell functions in vitro and in vivo and on the development of several autoimmune 
diseases using mouse models.  
To assess the impact of salt on homeostasis and immune cell function, we provided mice with 
normal drinking water (NDW) or salt drinking water containing 1% NaCl (SDW) for a period 
of three weeks during which fresh urine and stool samples were collected. Albeit increased 
water intake, neither urine-specific gravity nor feacal IgA levels were affected by SDW. IgA 
is a measure of impairment in the intestinal mucosa; it is excreted from the lamina propria 
after translocation of microbial products when the epithelial barrier gets impaired. 
Nevertheless, pre-exposure to SDW lead to elevated numbers of F4/80+CD11b+ peritoneal 
cells and to increased production of IL-2, TNFα and IL-17A by CD4+ T cells ex vivo. In line 
with previous studies (140, 141, 217–219), we show that in vitro exposure to salt also effects 
T-cell and macrophage effector functions. However, reduced viability for both was observed 
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as well. Moreover, we indicate that the effects were partially mediated through osmotic 
mechanisms since similar results were obtained by D-mannitol.  
To determine if SDW can affect the development of T-cell mediated autoimmunity, we 
studied EAE and CIA in mice provided with NDW or SDW. However, and contrary to that 
observed in EAE under HSD, we did not observe differences in disease development in either 
EAE or CIA. It has to be noted that the salt concentration used in our study is drastically 
lower compared to that used as HSD in previous EAE studies. Moreover, our mice express a 
MHC-II H-2q molecule, whereas B6 mice used in the previous studies express H-2b, which 
might cause a difference in the strength and duration of the generated T-cell responses (220). 
Furthermore, all mice developed a very severe form of EAE, leaving a very small window to 
worsen the disease.  
Macrophages are known to play a crucial role in the development of antibody-mediated 
autoimmunity (6, 221). Since we found increased numbers of macrophages and expansion of 
both pro- and anti-inflammatory cytokines, we assessed whether antibody-mediated arthritis 
could be influenced by SDW. During the initial phase of CAIA, mice exposed to SDW 
developed less arthritis. However, this was completely abrogated after LPS stimulation. A 
possible explanation for this is increased infiltration of inflammatory macrophages and 
neutrophils after LPS stimulation (6, 201).  
 
Figure 7 Exposure to high salt intake exacerbates the severity of dextran sulphate sodium (DSS)-induced colitis. (a) 
Mice were pre-exposed to 1% NaCl in water or standard drinking water for 3 weeks, followed by 5% DSS for 1 week, and 
again 1% NaCl in water or standard drinking water for another 1 week. (b) Faecal IgA titres from colitis mice described in 
(a) compared with naïve mice under identical salty water regiments. (c) Colitis disease symptoms were monitored daily 
and presented as disease activity index (DAI) score and prevalence. (d) Absolute cell numbers in spleen and mesenteric 
lymph nodes of mice 14 days after DSS exposure. Adapted from (143). 
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Since dietary factors have shown to influence the microbiota and immune cell signatures in 
the gut, we hypothesized that salt would have an adverse effect on DSS-induced colitis in 
mice, an inflammatory disease of the gut. This was indeed the case and in line with recently 
published studies (222, 223). Mice with SDW have exacerbated colitis symptoms (Figure 7), 
increased levels of IgA, decreased colon length caused by increased microscopic 
inflammation, increased number of lymphocytes, elevated levels of macrophages in the colon 
and higher number of TNFa on both CD4+ T cells and macrophages in the colon. 
Interestingly, the observed disease phenotype was independent of its osmotic properties, since 
D-mannitol resulted in a similar disease phenotype as mice on NDW.  
Taken together, we show that exposing mice to moderate salt concentrations influenced the 
effector functions of naïve T lymphocytes and myeloid cells, in particular macrophages, with 
pathological consequences during the development of inflammatory diseases, particularly 
leading to exacerbated disease symptoms in colitis, but not in T-cell mediated autoimmunity.  
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2.3 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
With the work presented in this thesis, I have contributed to a further understanding of 
the complexity that is autoimmunity. I have addressed both the effects of genetic and 
environmental factors on the development of autoimmune diseases using mouse models. 
Paper I identifies that polymorphisms in both FcγR2b and FcγR3 regulate the severity of 
inflammatory responses. This observation highlights the importance of genetic interplay in 
the regulation of autoimmunity and the relevance of using congenic mice. Paper II 
determines that SNAT proteins regulate T cell activation in vitro and that blocking them 
diminishes the severity of antibody-mediated arthritis in vivo. This reduction most likely 
occurs through MeAIBs effect on metabolically active inflammatory cells. Targeting immune 
cell metabolism might thus be beneficial for treatment purposes. Paper III concludes that 
moderate salt intake exacerbates DSS induced colitis phenotypes caused by changes in T cell 
and macrophage signatures in vivo. Phenotypic immune cell changes were not translated into 
T-cell dependent autoimmunity. These findings highlight the regulation of macrophage-
dependent pathologies by salt.  
In papers I and II, I have shown the importance of using congenic mice to identify arthritis 
causative genes. Although congenic mice were not used as such in paper II, it was the 
information obtained from congenic mouse studies that led us in this direction. The use of 
MeAIB to target SNAT proteins for treatment of arthritis in human disease is not likely 
unfortunately due to its high uptake by the liver. However, it is likely that current arthritis 
treatments, affecting cell proliferation, already target SNAT proteins. Nevertheless, this has 
yet to be investigated, as well as a therapeutic approach that could solely affect the 
metabolism of immune cells.  
Clinical data has demonstrated the role of FcγR polymorphisms and their binding affinity in 
treatment responses in RA patients. Moreover, various strategies for FcγR targeting exist for 
clinical intervention in autoimmunity, such as blocking FcγRs, neutralizing circulating 
immune complexes, use of bispecific ligands (e.g. crosslinking FcγR2b with the BCR on B 
cells) or antibody modification to manipulate binding affinity and reduce inflammatory 
responses. However, there is still need for a better understanding of the individual FcγR 
function on individual cell types.  
Taken together, I have shown that the interaction between two genes enhances arthritis 
disease development, whereas a single environmental factor has no impact on arthritis albeit 
triggering the immune system. These results contribute to the understanding of the 
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mechanism behind complex multifactorial diseases as a small building block towards 
therapeutic intervention. 
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